myqorzo
Generic: aficamten
myqorzo: developed by 1 company · 3 FDA decisions. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| CYTOKINETICS INC (CYTK) | Approved |
FDA Decisions
FDA_MeetingFDA and company discussed safety and risk mitigation prior to NDA submission; NDA was filed without REMS based on those discussions.(CYTK)
Approval1 INDICATIONS AND USAGE MYQORZO is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. MYQORZO is a cardiac myosin inhibitor indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. ( 1 )(CYTK)
Frequently asked questions
Who is developing myqorzo?
myqorzo is being developed by CYTOKINETICS INC.
What is myqorzo's latest FDA decision?
The most recent tracked FDA decision for myqorzo is FDA_Meeting for FDA and company discussed safety and risk mitigation prior to NDA submission; NDA was filed without REMS based on those discussions..
Get deeper analysis on myqorzo
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis